Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 1: Background and Methods of the Development of Guidelines.

Fountoulakis KN, Young A, Yatham L, Grunze H, Vieta E, Blier P, Moeller HJ, Kasper S.

Int J Neuropsychopharmacol. 2017 Feb 1;20(2):98-120. doi: 10.1093/ijnp/pyw091.

2.

Pharmaceutical Innovation in the Treatment of Schizophrenia and Mental Disorders Compared with Other Diseases.

MacEwan JP, Seabury S, Aigbogun MS, Kamat S, van Eijndhoven E, Francois C, Henderson C, Citrome L.

Innov Clin Neurosci. 2016 Aug 1;13(7-8):17-25. eCollection 2016 Jul-Aug.

3.

Effects of Omega-3 Supplement in the Treatment of Patients with Bipolar I Disorder.

Shakeri J, Khanegi M, Golshani S, Farnia V, Tatari F, Alikhani M, Nooripour R, Ghezelbash MS.

Int J Prev Med. 2016 May 19;7:77. doi: 10.4103/2008-7802.182734. eCollection 2016.

4.

A Lifetime Prevalence of Comorbidity Between Bipolar Affective Disorder and Anxiety Disorders: A Meta-analysis of 52 Interview-based Studies of Psychiatric Population.

Nabavi B, Mitchell AJ, Nutt D.

EBioMedicine. 2015 Sep 8;2(10):1405-19. doi: 10.1016/j.ebiom.2015.09.006. eCollection 2015 Oct.

5.

Management of bipolar disorders in women by nonpharmacological methods.

Naik SK.

Indian J Psychiatry. 2015 Jul;57(Suppl 2):S264-74. doi: 10.4103/0019-5545.161490. Review.

6.

Dietary intake and plasma metabolomic analysis of polyunsaturated fatty acids in bipolar subjects reveal dysregulation of linoleic acid metabolism.

Evans SJ, Ringrose RN, Harrington GJ, Mancuso P, Burant CF, McInnis MG.

J Psychiatr Res. 2014 Oct;57:58-64. doi: 10.1016/j.jpsychires.2014.06.001. Epub 2014 Jun 12.

7.

Correlates of real world executive dysfunction in bipolar I disorder.

Peters AT, Peckham AD, Stange JP, Sylvia LG, Hansen NS, Salcedo S, Rauch SL, Nierenberg AA, Dougherty DD, Deckersbach T.

J Psychiatr Res. 2014 Jun;53:87-93. doi: 10.1016/j.jpsychires.2014.02.018. Epub 2014 Mar 2.

8.

Cognitive behavioral therapy for insomnia in euthymic bipolar disorder: study protocol for a randomized controlled trial.

Steinan MK, Krane-Gartiser K, Langsrud K, Sand T, Kallestad H, Morken G.

Trials. 2014 Jan 16;15:24. doi: 10.1186/1745-6215-15-24.

9.

Sexually dimorphic, developmental, and chronobiological behavioral profiles of a mouse mania model.

Saul MC, Stevenson SA, Gammie SC.

PLoS One. 2013 Aug 13;8(8):e72125. doi: 10.1371/journal.pone.0072125. eCollection 2013.

10.

Treatment use and costs among privately insured youths with diagnoses of bipolar disorder.

Dusetzina SB, Farley JF, Weinberger M, Gaynes BN, Sleath B, Hansen RA.

Psychiatr Serv. 2012 Oct;63(10):1019-25.

11.

Metabolic syndrome in Tunisian bipolar I patients.

Ezzaher A, Haj MD, Mechri A, Neffati F, Douki W, Gaha L, Najjar MF.

Afr Health Sci. 2011 Sep;11(3):414-20.

12.

Determinants of occupational and residential functioning in bipolar disorder.

Depp CA, Mausbach BT, Bowie C, Wolyniec P, Thornquist MH, Luke JR, McGrath JA, Pulver AE, Harvey PD, Patterson TL.

J Affect Disord. 2012 Feb;136(3):812-8. doi: 10.1016/j.jad.2011.09.035. Epub 2011 Nov 29.

13.

Customization in prescribing for bipolar disorder.

Hodgkin D, Volpe-Vartanian J, Merrick EL, Horgan CM, Nierenberg AA, Frank RG, Lee S.

Health Econ. 2012 Jun;21(6):653-68. doi: 10.1002/hec.1737. Epub 2011 Apr 19.

14.

Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder.

Squassina A, Manchia M, Del Zompo M.

Hum Genomics Proteomics. 2010 Aug 3;2010:159761. doi: 10.4061/2010/159761.

15.

Pattern of healthcare resource utilization and direct costs associated with manic episodes in Spain.

Tafalla M, Salvador-Carulla L, Saiz-Ruiz J, Diez T, Cordero L.

BMC Psychiatry. 2010 Apr 28;10:31. doi: 10.1186/1471-244X-10-31.

16.

Treating bipolar disorder in the primary care setting: the role of aripiprazole.

Manning JS, McElroy SL.

Prim Care Companion J Clin Psychiatry. 2009;11(5):245-57. doi: 10.4088/PCC.08r00635.

17.

Difficult to swallow: patient preferences for alternative valproate pharmaceutical formulations.

Bhosle M, Benner JS, Dekoven M, Shelton J.

Patient Prefer Adherence. 2009 Nov 3;3:161-71.

18.

Impact of bipolar disorder on the family: utilization and cost of health care resources.

Chatterton ML, Ke X, Lewis BE, Rajagopalan K, Lazarus A.

P T. 2008 Jan;33(1):15-34.

19.

Carbamazepine extended-release capsules in bipolar disorder.

Weisler RH.

Neuropsychiatr Dis Treat. 2006 Mar;2(1):3-11.

Supplemental Content

Support Center